Strong Merck cancer drug sales upstage rival Bristol-Myers

April 28 (Reuters) - Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.